# A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

> **NCT05461768** · PHASE1 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 26 (estimated)

## Conditions studied

- Breast Cancer
- Locally Advanced or Metastatic Solid Tumor

## Interventions

- **DRUG:** BL-M07D1

## Key facts

- **NCT ID:** NCT05461768
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-09
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05461768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05461768, "A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05461768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*